|
1. |
Neuroprotection in Hungtington's Disease |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 223-224
Theresa Lahousen,
RM Bonelli,
Preview
|
PDF (104KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
2. |
Neuroprotection in Hungtington's Disease: RESPONSE FROM THE AUTHORS |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 224-224
Madhavi Thomas,
Wei Le,
Joseph Jankovic,
Preview
|
PDF (104KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
3. |
Improvement of Ataxia in Cortical Cerebellar Atrophy With the Drug Gabapentin |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 225-226
José Gazulla,
José Errea,
Isabel Benavente,
Carlos Tordesillas,
Preview
|
PDF (103KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
4. |
Poor Tolerability of a Transdermal Nicotine Treatment in Parkinson's Disease |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 227-229
Simon Lemay,
Pierre Blanchet,
Sylvain Chouinard,
Hélène Masson,
Valérie Soland,
Marc-André Bédard,
Preview
|
PDF (151KB)
|
|
摘要:
Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transdermal nicotine in PD. Twenty-two therapeutically well-controlled nonsmoking PD patients received a transdermal nicotine treatment over 25 days according to the following fixed titration schedule: 7 mg for the first 11 days, 14 mg for the next 11 days, and 21 mg for the last 3 days. Fourteen PD patients (64%) had side effects such as nausea, vomiting, and dizziness, and 10 of them withdrew from the study. Factors such as age, body mass index, disease duration, and motor disability were not related to this intolerance. Transdermal nicotine can produce unpleasant adverse effects in patients with PD. Given that similar doses of nicotine were better tolerated in previous studies, the authors suspect the pharmacokinetic profile of the transdermal delivery system to be a determining factor in the effect of nicotine treatment in PD.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
5. |
Addition of a Dopamine Agonist, Cabergoline, to a Serotonin-Noradrenalin Reuptake Inhibitor, Milnacipran as a Therapeutic Option in the Treatment of Refractory Depression: Two Case Reports |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 230-232
Hitoshi Takahashi,
Keizo Yoshida,
Hisashi Higuchi,
Tetsuo Shimizu,
Takeshi Inoue,
Tsukasa Koyama,
Preview
|
PDF (143KB)
|
|
摘要:
We illustrate 2 patients with depression who attained dramatic improvement of energy loss and fatigue when treated with cabergoline, a dopamine agonist, and milnacipran, a serotonin-noradrenalin reuptake inhibitor. Although the biologic basis of energy, motivation, and fatigue in association with depression remains unknown, some reports suggest that the decrease of noradrenalin and dopamine in the brain are particularly related to these symptoms. Therefore, treatment strategy that enhances these two monoamine neurotransmissions may be appropriate for getting a boost in energy and eliminating fatigue in patients with depression. These cases suggest that further studies are warranted to confirm the potential benefit of this strategy in the treatment of patients with depression who failed to attain complete remission due to residual symptoms including energy loss and fatigue refractory to previous treatments.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
6. |
Lamotrigine Treatment for Post-Stroke Pathological Laughing and Crying |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 233-235
Rajamannar Ramasubbu,
Preview
|
PDF (149KB)
|
|
摘要:
Pathologic laughing and crying (PLC) is a common distressing and socially disabling condition in stroke patients. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been increasingly recognized as the treatment of choice for pathologic crying (PC). However, little is known about etiologies and other treatment options for various clinical manifestations of PLC. This case report illustrates the beneficial effect of lamotrigine, a novel antiepileptic drug with antidepressant and mood-stabilizing properties in post-stroke PLC. A 60-year-old woman developed PLC after an ischemic stroke affecting the left frontal and temporal lobes. She was treated with lamotrigine initially at the dose of 50 mg a day, which was gradually increased to 100 mg a day over a 4-week period. There was a significant and rapid recovery in both laughing and crying components of PCL with lamotrigine treatment. The symptoms of pathologic laughing have shown a better response to lamotrigine than PC. Controlled investigations are needed to evaluate the beneficial as well as the differential effects of lamotrigine on PLC.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
7. |
Drug-Induced Pseudotumor Cerebri |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 236-238
A.B.M. Uddin,
Preview
|
PDF (148KB)
|
|
摘要:
Pseudotumor Cerebri (PTC) is an uncommon disorder whose etiology is largely unknown, although its association with steroid withdrawal, hypervitaminosis A, and the use of the tetracycline group of drugs has been well documented. We report here a case in which a patient on chronic divalproex therapy for a seizure disorder developed PTC. Changing his antiepileptic medication from divalproate to topiramate effected a remission of PTC symptoms while maintaining his seizure-free status. It is recommended that physicians treating epilepsy, vascular headaches, or mood disorders with divalproate consider the diagnosis of PTC when their patients complain of new onset of headaches or an increase in frequency or severity of existing headaches—especially those associated with a visual disturbance—to prevent permanent visual loss.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
8. |
The Effects of a Cholinesterase Inhibitor Are Prominent in Patients With Fluctuating Cognition: A Part 3 Study of the Main Mechanism of Cholinesterase Inhibitors in Dementia |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 239-251
Marco Onofrj,
Astrid Thomas,
Diego Iacono,
Anna Lisa Luciano,
Angelo Di Iorio,
Preview
|
PDF (646KB)
|
|
摘要:
Fluctuating cognition is evidenced in different forms of dementia and is accompanied by electroencephalographic (EEG) abnormalities. The authors hypothesize that cholinesterase inhibitors are effective mostly in patients with fluctuating cognition. Twenty-three patients affected by mild dementia with similar scores on Mini-Mental State Examination (MMSE), Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), and Unified Parkinson's Disease Rating Scale evaluation were classified in a group with fluctuating cognition (n = 11) and a group of nonfluctuators (n = 12). All patients were assigned randomly to the branches of a double-blind crossover study of donepezil (DPZ), a 5 to 10-mg dose, versus vitamin E, a 2000 IU dose, for 30 days. MMSE, ADAS-cog, University of California at Los Angeles Neuropsychiatric Inventory (NPI), quantitative EEG, P3 event-related potentials, choice reaction time variability (CRTV) were assessed at baseline and at the end of treatments. At the end of the crossover study all patients received DPZ for 6 months. The dominant EEG frequency variability, low EEG frequencies amplitude, the P3 latency and jitter, CRTV, and NPI was significantly different in the fluctuating cognition group than the nonfluctuating group at baseline (P < 0.001). Short-term DPZ administration induced a significant increase in MMSE scores, reduction of ADAS-cog and of NPI scores (P < 0.003–0.001), increase of EEG &agr; activity and reductions of P3 latency and jitter, dominant frequency variability and CRTV (P < 0.009-0.001) in the fluctuating cognition group, and significant increases of MMSE scores (P = 0.03) and a decrease of P3 jitter and dominant frequency variability (P < 0.034–0.041) in the nonfluctuating group. Short-term DPZ effects differed significantly between fluctuating cognition and nonfluctuating patients (0.001). Significant effects of the 6-month observation were observed only in fluctuating cognition patients. Logistic analysis showed that P3 latency predicts the effect of DPZ (P= 0.04,P< 0.01) in the crossover study, and CRTV predicts the effect at the 6-month follow-up.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
9. |
Dosing Regimen Effects of Modafinil for Improving Daytime Wakefulness in Patients With Narcolepsy |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 252-257
Jonathan Schwartz,
Neil Feldman,
Richard Bogan,
Michael Nelson,
Rod Hughes,
Preview
|
PDF (296KB)
|
|
摘要:
In a multicenter, randomized, double-blind study the authors compared the efficacy of modafinil 400 mg once daily, 400 mg given in a split dose, or 200 mg once daily for maintaining wakefulness throughout the day in patients (N = 32) with narcolepsy reporting a positive daytime response to modafinil but late-afternoon/evening sleepiness. Efficacy evaluations included an extended Maintenance of Wakefulness Test (9:00 am to 9:00 pm), the Clinical Global Impression of Change scale, and the Epworth Sleepiness Scale. Modafinil demonstrated significant improvement in wakefulness as assessed by the Epworth Sleepiness Scale compared with placebo at baseline (allP< 0.001). Modafinil significantly improved patients' ability to sustain wakefulness, as demonstrated by mean sleep latency at week 3 compared with placebo at baseline (allP< 0.001). The 400-mg split-dose regimen improved wakefulness significantly in the evening compared with the 200-mg and 400-mg once-daily regimen (bothP< 0.05). The percentage of patients rated as “much improved” or “very much improved” with respect to evening sleepiness was 27%, 82%, and 80% in the 200-mg, 400-mg once-daily, and 400-mg split-dose groups, respectively. Adverse events were mild to moderate in nature and included headache, nausea, nervousness, dyspepsia, pain, and vomiting (all 6%). Some patients may benefit from 400-mg doses of modafinil taken once daily compared with 200-mg doses. A split-dose 400-mg regimen may be superior to once-daily dosing for sustaining wakefulness throughout the entire waking day.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
10. |
Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report |
|
Clinical Neuropharmacology,
Volume 26,
Issue 5,
2003,
Page 258-262
Giovanni Addolorato,
Lorenzo Leggio,
Ludovico Abenavoli,
Giosue DeLorenzi,
Antonio Parente,
Fabio Caputo,
Luigi Janiri,
Esmeralda Capristo,
Gian Rapaccini,
Giovanni Gasbarrini,
Preview
|
PDF (239KB)
|
|
摘要:
Delirium tremens (DT) is a clinical condition that appears in some patients affected by severe alcohol withdrawal syndrome (AWS). DT represents a serious complication, being characterized by elevated morbidity and mortality. Benzodiazepines are presently the drug of choice; however their use is related to several side effects. Baclofen is a stereoselective &ggr;-aminobutyric acid (GABAB) receptor agonist. Recent studies show that baclofen is able to suppress alcohol withdrawal symptoms. At present there are no data on the effects of baclofen administration in AWS complicated by DT. Here, we report a case of DT successfully treated with baclofen. This result indicates that the efficacy of baclofen in the treatment of DT should be examined in future clinical trials.
ISSN:0362-5664
出版商:OVID
年代:2003
数据来源: OVID
|
|